Stephen Futterweit

Summary

Affiliation: Long Island Jewish Medical Center
Country: USA

Publications

  1. pmc IgA nephropathy: a twenty year retrospective single center experience
    Jacob Rube
    Department of Pediatrics Division of Nephrology, Schneider Children s Hospital, New Hyde Park, New York
    Clin Med Pediatr 3:19-22. 2009
  2. pmc Hydronephrosis in infants and children: natural history and risk factors for persistence in children followed by a medical service
    Kristy VanDervoort
    Departments of Pediatrics and Radiology, Schneider Children s Hospital of the North Shore LIJ Health System, New Hyde Park, NY email
    Clin Med Pediatr 3:63-70. 2009
  3. pmc Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome
    Ashton Chen
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of North Shore Long Island Jewish Health System, New Hyde Park, NY 11040 1432, USA
    BMC Nephrol 8:11. 2007
  4. pmc Diagnostic yield of renal biopsies: a retrospective single center review
    Bari Scheckner
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital, New Hyde Park, New York of North Shore LIJ Health System, Long Island Campus of the Albert Einstein College of Medicine, New York, USA
    BMC Nephrol 10:11. 2009
  5. pmc Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group
    Alexandra Peyser
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of North Shore LIJ Health System, 269 01 76th Avenue, New Hyde Park, NY 11040, USA
    BMC Nephrol 11:2. 2010
  6. ncbi Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction
    Howard Trachtman
    Department of Pediatrics, Schneider Children s Hospital, New Hyde Park, New York 11040, USA
    J Urol 172:1590-4. 2004
  7. doi Minority report
    Howard Trachtman
    Schneider Children s Hospital, New Hyde Park 11040, USA
    Am J Bioeth 8:34-5. 2008
  8. ncbi Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial
    Howard Trachtman
    Department of Pediatrics, Schneider Children s Hospital of the North Shore Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    JAMA 290:1337-44. 2003
  9. doi Pilot study of mycophenolate mofetil for treatment of kidney disease due to congenital urinary tract disorders in children
    Howard Trachtman
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of North Shore LIJ Health System, New Hyde Park, New York, NY 11040, USA
    Am J Kidney Dis 52:706-15. 2008
  10. ncbi Spinoza's Passions
    Howard Trachtman
    Pediatrics Nephrology, Schneider Children s Hospital, New Hyde Park, NY 11040, USA
    Am J Bioeth 7:21-3. 2007

Research Grants

  1. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 2000
  2. MULTICENTER TRIAL OF SYNSORB PK IN E COLI
    Howard Trachtman; Fiscal Year: 1999
  3. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 2000
  4. Novel Therapies for Resistant FSGS
    Howard Trachtman; Fiscal Year: 2006
  5. Human monoclonal antibody therapy for HUS
    Howard Trachtman; Fiscal Year: 2004
  6. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 1999
  7. International Network and Registry for TMA
    Howard Trachtman; Fiscal Year: 2007
  8. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 2003
  9. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 2002

Detail Information

Publications65

  1. pmc IgA nephropathy: a twenty year retrospective single center experience
    Jacob Rube
    Department of Pediatrics Division of Nephrology, Schneider Children s Hospital, New Hyde Park, New York
    Clin Med Pediatr 3:19-22. 2009
    ....
  2. pmc Hydronephrosis in infants and children: natural history and risk factors for persistence in children followed by a medical service
    Kristy VanDervoort
    Departments of Pediatrics and Radiology, Schneider Children s Hospital of the North Shore LIJ Health System, New Hyde Park, NY email
    Clin Med Pediatr 3:63-70. 2009
    ..There is little current information about the natural history of children with hydronephrosis or clinical factors that predict resolution of the radiological abnormality...
  3. pmc Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome
    Ashton Chen
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of North Shore Long Island Jewish Health System, New Hyde Park, NY 11040 1432, USA
    BMC Nephrol 8:11. 2007
    ..We conducted this study to evaluate pediatric patients with IMN in order to clarify the presentation, response to therapy, and clinical outcome...
  4. pmc Diagnostic yield of renal biopsies: a retrospective single center review
    Bari Scheckner
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital, New Hyde Park, New York of North Shore LIJ Health System, Long Island Campus of the Albert Einstein College of Medicine, New York, USA
    BMC Nephrol 10:11. 2009
    ..This retrospective, single-center chart review was performed to test the hypothesis that at least 80% of native kidney biopsies provide clinically valuable information that rationally guides diagnosis and patient management...
  5. pmc Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group
    Alexandra Peyser
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of North Shore LIJ Health System, 269 01 76th Avenue, New Hyde Park, NY 11040, USA
    BMC Nephrol 11:2. 2010
    ..Antifibrotic agents may slow or halt this process. We present outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibrotic drugs tested in the Novel Therapies in Resistant FSGS (FONT) study...
  6. ncbi Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction
    Howard Trachtman
    Department of Pediatrics, Schneider Children s Hospital, New Hyde Park, New York 11040, USA
    J Urol 172:1590-4. 2004
    ..We conducted experiments to determine whether administration of spironolactone, a mineralocorticoid receptor antagonist, reduced renal fibrosis in an experimental model of obstructive uropathy...
  7. doi Minority report
    Howard Trachtman
    Schneider Children s Hospital, New Hyde Park 11040, USA
    Am J Bioeth 8:34-5. 2008
  8. ncbi Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial
    Howard Trachtman
    Department of Pediatrics, Schneider Children s Hospital of the North Shore Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    JAMA 290:1337-44. 2003
    ..Diarrhea-associated hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in children. Most cases are caused by an intestinal infection with Shiga toxin-producing strains of Escherichia coli...
  9. doi Pilot study of mycophenolate mofetil for treatment of kidney disease due to congenital urinary tract disorders in children
    Howard Trachtman
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of North Shore LIJ Health System, New Hyde Park, New York, NY 11040, USA
    Am J Kidney Dis 52:706-15. 2008
    ..Congenital uropathies account for nearly half the chronic kidney disease in children. Immune-mediated injury may contribute to progressive loss of kidney function in affected patients...
  10. ncbi Spinoza's Passions
    Howard Trachtman
    Pediatrics Nephrology, Schneider Children s Hospital, New Hyde Park, NY 11040, USA
    Am J Bioeth 7:21-3. 2007
  11. ncbi Nitric oxide and superoxide in rat mesangial cells: modulation by C-reactive protein
    Howard Trachtman
    Department of Pediatrics Division of Nephrology, Schneider Children s Hospital, Albert Einstein College of Medicine, New Hyde Park, NY 11040 1432, USA
    Pediatr Nephrol 21:619-26. 2006
    ..C-reactive protein (CRP) has been linked to cardiovascular and renal disease. We evaluated the effects of CRP on the production of nitric oxide (NO) and superoxide by rat mesangial cells (RMC) and the impact on cell function...
  12. ncbi Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury
    Howard Trachtman
    Department of Pediatrics Division of Nephrology, Schneider Children s Hospital of the North Shore Long Island Jewish Medical Center, New Hyde Park, New York, NY, USA
    Pediatr Nephrol 21:989-94. 2006
    ..Diarrhea-associated hemolytic uremic syndrome (D+HUS) causes acute renal failure. Neutrophil gelatinase-associated lipocalcin (NGAL) is an early indicator of kidney injury...
  13. ncbi A microscopic view of medical care and its costs
    Howard Trachtman
    Schneider Children s Hospital, Division of Nephrology, 269 01 76th Ave, New Hyde Park, NY 11040, USA
    Pediatrics 118:2220-1. 2006
  14. ncbi Glomerular permeability activity: prevalence and prognostic value in pediatric patients with idiopathic nephrotic syndrome
    Howard Trachtman
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of North Shore Long Island Jewish Health System, Long Island Campus for Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA
    Am J Kidney Dis 44:604-10. 2004
    ..The prevalence and prognostic significance of permeability activity has not been examined in children with idiopathic nephrotic syndrome (INS)...
  15. ncbi Nitric oxide and glomerulonephritis
    Howard Trachtman
    Department of Pediatrics, Schneider Children s Hospital of Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, New York 11040, USA
    Semin Nephrol 24:324-32. 2004
    ..It is hoped that better understanding of the role of NO in glomerulonephritis will lead to the development of therapies to ameliorate the disease...
  16. ncbi Chronic diabetic nephropathy: role of inducible nitric oxide synthase
    Howard Trachtman
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of the North Shore Long Island Jewish Health System, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, NY, USA
    Pediatr Nephrol 17:20-9. 2002
    ..This action is probably a result of the direct actions of NO on the synthesis and degradation of extracellular matrix proteins...
  17. ncbi Clinical trial of extended-release felodipine in pediatric essential hypertension
    Howard Trachtman
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of the North Shore LIJ Health System, New Hyde Park, NY 11040, USA
    Pediatr Nephrol 18:548-53. 2003
    ..Further studies are needed to clarify the role of felodipine ER in the management of children and adolescents with essential hypertension...
  18. ncbi Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells
    H Trachtman
    Department of Pediatrics, Schneider Children s Hospital, New Hyde Park, NY 11040 1432, USA
    Biochem Biophys Res Commun 229:243-8. 1996
    ..Moreover, CMT-induced changes in NO synthesis were associated with parallel alterations in steady-state iNOS mRNA abundance and protein expression. These agents may be useful to ameliorate NO-dependent glomerular inflammation...
  19. ncbi Renal tubular epithelial cell-E. coli interaction products stimulate nitric oxide production in cultured rat renal medullary interstitial and mesangial cells
    H Trachtman
    Department of Pediatrics, Schneider Children s Hospital, New Hyde Park, NY 11040 1432, USA
    Res Commun Mol Pathol Pharmacol 94:227-38. 1996
    ..coli interaction products increase NO production in RMIC and MC by directly stimulating iNOS enzymatic activity. Altered NO production by renal cells may contribute to tubulointerstitial inflammation in acute and chronic pyelonephritis...
  20. ncbi Effect of vascular endothelial growth factor on nitric oxide production by cultured rat mesangial cells
    H Trachtman
    Department of Pediatrics, Schneider Children s Hospital of Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA
    Biochem Biophys Res Commun 245:443-6. 1998
    ..These findings suggest that disturbances in the normal interaction between VEGF and NO are not involved in the pathogenesis of abnormal mesangial cell structure or function in diabetic nephropathy...
  21. ncbi Diagnosis and treatment of chronic renal failure in children
    H Trachtman
    Schneider Children s Hospital, New Hyde Park, NY 11040, USA
    Am J Manag Care 3:785-8; quiz 793. 1997
    ..This activity is designed for primary care and specialist physicians...
  22. ncbi Anti-apoptotic effect of L-arginine in cultured rat mesangial cells
    H Trachtman
    Schneider Children s Hospital, Division of Nephrology, NY 11040 1432, USA
    Int J Mol Med 6:485-9. 2000
    ..These findings indicate that several components of the nitric oxide biosynthetic pathway including the precursor and the enzymatic product independently exert direct effects on apoptosis in cultured rat mesangial cells...
  23. ncbi Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis
    Roy Mathew
    Schneider s Children s Hospital, Division of Nephrology, SCH 365, 269 01 76th Ave, New Hyde Park, NY 11040 1432, USA
    Am J Physiol Renal Physiol 289:F911-21. 2005
    ..MEP-alpha may play a role in the pathogenesis of DN and the benefits of ACE inhibitor therapy on the progression of diabetic kidney disease may be related, in part, to its impact on renal MEP-alpha expression...
  24. doi Evaluation of pediatric patients with mild-to-moderate hypertension: yield of diagnostic testing
    Jonathan Wiesen
    Division of Nephrology, Department of Pediatrics, Schneider Children s Hospital of North Shore LIJ Health System, Long Island Campus, Albert Einstein College of Medicine, New Hyde Park, New York 11040, USA
    Pediatrics 122:e988-93. 2008
    ..We tested the hypothesis that the diagnostic yield of individual components of the currently recommended assessment does not justify performance for all patients with mild-to-moderate hypertension...
  25. pmc A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis
    Howard Trachtman
    Division of Nephrology, Department of Pediatrics, Cohen Children s Medical Center, New Hyde Park, New York, USA
    Kidney Int 79:1236-43. 2011
    ..Thus, single-dose fresolimumab was well tolerated in patients with primary resistant FSGS. Additional evaluation in a larger dose-ranging study is necessary...
  26. pmc Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
    Howard Trachtman
    Cohen Children s Medical Center of New York, North Shore Long Island Jewish Health System, New Hyde Park, NY, USA
    BMC Nephrol 12:8. 2011
    ..There is a need for a flexible Phase II study design which will test such novel antifibrotic strategies in order to identify agents suitable for phase III testing...
  27. pmc Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion
    Liora Adler
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of the North Shore Long Island Jewish Health System, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, NY, USA
    BMC Nephrol 3:2. 2002
    ..We evaluated the effect of short-term therapy with the angiotensin converting enzyme inhibitor, enalapril, in early Alport syndrome, defined as disease duration less than 10 years and a normal glomerular filtration rate...
  28. ncbi Urinary podocyte mRNA excretion in children with D+HUS: a potential marker of long-term outcome
    Laura De Petris
    Department of Pediatrics, Washington University, St Louis, Missouri, USA
    Ren Fail 28:475-82. 2006
    ..Objective. To determine if the urinary mRNA excretion of podocyte proteins is detectable in children with D+HUS and if it is a biomarker of a poor long-term outcome...
  29. ncbi Cytoprotective effect of curcumin in human proximal tubule epithelial cells exposed to shiga toxin
    A Sood
    Department of Pediatrics, Schneider Children's Hospital of the North Shore-Long Island Jewish Health System, Albert Einstein College of Medicine, New Hyde Park, New York, 11040-1432, USA
    Biochem Biophys Res Commun 283:36-41. 2001
    ..The cytoprotective effect of curcumin against Stx-induced injury in cultured human proximal tubule epithelial cells may be a consequence of increased expression of HSP70...
  30. pmc Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome
    Joshua M Thurman
    Department of Medicine, Division of Nephrology, University of Colorado, Denver School of Medicine, Aurora, CO, USA
    Clin J Am Soc Nephrol 4:1920-4. 2009
    ..Therefore, we determined whether plasma levels of markers of activation of the AP are increased in D+HUS and are biomarkers of the severity of renal injury that predict the need for dialysis...
  31. ncbi Nitric oxide in obstructive uropathy: role of endothelial nitric oxide synthase
    Barry Chang
    Department of Pediatrics, Division of Urology, Schneider Children s Hospital, Long Island Jewish Medical Center, New Hyde Park, NY, USA
    J Urol 168:1801-4. 2002
    ....
  32. ncbi Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years
    Howard Trachtman
    Division of Pediatric Nephrology, Schneider Children s Hospital, New Hyde Park, NY, USA
    J Clin Hypertens (Greenwich) 10:743-50. 2008
    ..Candesartan is an effective, well-tolerated antihypertensive agent for children aged 6 to 17 years and has a pharmacokinetic profile that is similar to that in adults...
  33. ncbi Urinary meprin-alpha: a potential marker of diabetic nephropathy
    Jocelyn B DeGuzman
    Department of Pediatrics, Divisions of Endocrinology, Schneider Children s Hospital, New Hyde Park, NY, USA
    J Pediatr Endocrinol Metab 17:1663-6. 2004
  34. ncbi Hypercalciuria in children with renal glycosuria: evidence of dual renal tubular reabsorptive defects
    D Schneider
    Department of Pediatrics, Schneider Children s Hospital of Long Island Jewish Medical Center, New Hyde Park, New York 11042
    J Pediatr 121:715-9. 1992
    ..It is likely that a similar mechanism accounts for the idiopathic hypercalciuria in children with diabetes mellitus...
  35. ncbi Pediatric biopsy of a single native kidney
    L A Greenbaum
    Medical College of Wisconsin, Department of Pediatrics, Milwaukee 53226, USA
    Pediatr Nephrol 15:66-9. 2000
    ..We encourage our colleagues to report to the international registry in order to further document the safety of percutaneous biopsy of the single native kidney in children...
  36. ncbi Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome
    Inna Novak
    Department of Pediatrics, Division of Nephrology, Schneider Children s Hospital of the North Shore Long Island Jewish Health System, 269 01 76th Ave, New Hyde Park, NY 11040, USA
    Pediatr Nephrol 20:1265-8. 2005
    ..It lowers the relapse rate by 40% and is well tolerated by patients with steroid-dependent nephrotic syndrome...
  37. ncbi Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome
    Patricio Ray
    Department of Pediatrics, Children s National Medical Center, Washington, DC, USA
    J Am Soc Nephrol 13:699-707. 2002
    ....
  38. ncbi Outcome after renal transplantation in children: results of follow-up by nephrologists in a primary referral center
    Olanrewaju Adedoyin
    Division of Nephrology, Schneider Children s Hospital of the North Shore Long Island Jewish Health System, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, NY 11040 1432, USA
    Pediatr Transplant 7:479-83. 2003
    ..Problems rarely developed that required referral back to the transplant center for management. This approach to care is recommended because it is more likely to foster compliance by both patients and parents...
  39. ncbi A rose by any other name is still a rose
    Howard Trachtman
    Schneider Children s Hospital, USA
    Am J Bioeth 2:W19. 2002
  40. ncbi Cardiac disease in children with primary glomerular disorders-role of focal segmental glomerulosclerosis
    Olanrewaju Adedoyin
    Division of Nephrology, Schneider Children s Hospital of the North Shore Long Island Jewish Health System, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, New York, USA
    Pediatr Nephrol 19:408-12. 2004
    ..1). Our findings suggest that there is a clinical association between FSGS and cardiac disease in pediatric patients. We speculate that the immune mechanism responsible for the development of FSGS may also affect the heart...
  41. ncbi Clinical spectrum of gross hematuria in pediatric patients
    Trisha Youn
    Division of Pediatric Nephrology, Department of Pediatrics, Schneider Children s Hospital of the North Shore LIJ Health System, 269 01 76th Avenue, New Hyde Park, NY 11040, USA
    Clin Pediatr (Phila) 45:135-41. 2006
    ..Although nearly half of the patients with nonglomerular gross hematuria could not be given a diagnosis, their long-term prognosis appeared to be good...
  42. ncbi Prevention of serious bacterial infections in new-onset nephrotic syndrome: a survey of current practices
    Amita Shroff
    Department of Pediatrics, Schneider Children s Hospital of the North Shore Long Island Jewish Health System, Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA
    Clin Pediatr (Phila) 41:47-9. 2002
  43. ncbi Non-enteropathic hemolytic uremic syndrome: causes and short-term course
    Alex R Constantinescu
    Division of Pediatric Nephrology, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Am J Kidney Dis 43:976-82. 2004
    ....
  44. ncbi Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group
    Ronald J Hogg
    St Joseph s Hospital and Medical Center, Phoenix, AZ 85013, USA
    Clin J Am Soc Nephrol 1:1173-8. 2006
    ..It is concluded that MMF is effective for maintaining remission in patients who have FRNS and receive treatment for at least 6 mo and is associated with a low incidence of adverse events...
  45. ncbi Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy
    Sharon P Andreoli
    James Whitcomb Riley Hospital for Children, Well s Research Center, Room 2626, 702 Barnhill Drive, Indianapolis, IN 46223, USA
    Pediatr Nephrol 17:293-8. 2002
  46. ncbi Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study
    James C M Chan
    Virginia Commonwealth University, Richmond, Virginia, USA
    Pediatr Nephrol 18:1015-9. 2003
    ....
  47. ncbi Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF
    Matthew L Stoll
    Pediatr Nephrol 19:120-1. 2004
  48. pmc MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis
    Jeffrey B Kopp
    Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Genet 40:1175-84. 2008
    ..2, 95% CI = 1.5-3.4; n = 433), but not type 2 diabetic ESKD (n = 476). Genetic variation at the MYH9 locus substantially explains the increased burden of FSGS and hypertensive ESKD among African Americans...
  49. ncbi Clinico-pathologic findings in medullary cystic kidney disease type 2
    Anthony J Bleyer
    Section on Nephrology, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Pediatr Nephrol 20:824-7. 2005
    ....
  50. ncbi The Berlin Wall
    Howard Trachtman
    Schneider Children s Hospital
    Am J Bioeth 3:W4. 2003
  51. ncbi I thought we were in this together?
    Howard Trachtman
    Schneider Children s Hospital
    Am J Bioeth 2:30-1. 2002
  52. doi Introduction: education teaching article series on hemolytic uremic syndrome
    Howard Trachtman
    Pediatr Nephrol 23:1423-4. 2008
  53. ncbi A response to "Children in clinical research: a conflict of moral values" by Vera Hassner Sharav
    Howard Trachtman
    Am J Bioeth 3:W-C2. 2003
  54. ncbi Does uncle Sam really want you? A response to "Rethinking research Ethics" by Rosamond Rhodes (AJOB 5:1)
    Howard Trachtman
    Am J Bioeth 5:W22-3. 2005
  55. ncbi Facing the truth: A response to "On the ethics of facial transplantation research" by Wiggins et al
    Howard Trachtman
    Am J Bioeth 4:W33-4. 2004
  56. ncbi The secret sharer
    Howard Trachtman
    Am J Bioeth 6:W35. 2006
  57. ncbi The clinical trial imperative
    Debbie Gipson
    Pediatr Nephrol 20:5-9. 2005
    ..A review of the pediatric nephrology literature supports a call for general support of ongoing clinical trials and encourages the creation of additional feasible clinical trials to improve the practice of medicine...
  58. ncbi Modulating the progression in IgA nephropathy
    James C M Chan
    University of Vermont and the Barbara Bush Children s Hospital, Maine Medical Center, Portland, ME 04102 3175, USA
    Nephron Clin Pract 104:c61-8. 2006
    ..Therapeutic options are discussed including angiotensin-converting enzyme blockade, steroids, cytotoxics, tonsillectomy, fish oil, vitamin E, singly or in combination, in order to modulate the rate of progression...
  59. pmc Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome
    Saul Tzipori
    Division of Infectious Diseases, Tufts University School of Veterinary Medicine, 200 Westborough Rd, North Grafton, MA 01536, USA
    Clin Microbiol Rev 17:926-41, table of contents. 2004
    ..Such antibodies, even when administered well after exposure to bacterial infection and onset of diarrhea, can prevent the occurrence of systemic complications...
  60. ncbi The law of mass action
    Howard Trachtman
    Schneider Children s Hospital
    Am J Bioeth 6:72-4; discussion W42-5. 2006
  61. ncbi Teaching articles: a new goal of the journal
    Robert H Mak
    Pediatr Nephrol 22:24-5. 2007
  62. ncbi Educational feature on focal segmental glomerulosclerosis (FSGS): an introduction
    Howard Trachtman
    Pediatr Nephrol 22:26-7. 2007
  63. ncbi Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome
    Maria Victoria Ramos
    Division of Immunology, Institute of Hematological Investigations, Academia Nacional de Medicina, Buenos Aires, Argentina
    Blood 109:2438-45. 2007
    ..Finally, CX(3)CR1(+) leukocytes were observed in renal biopsies from patients with HUS. We suggest that the interaction of CX(3)CR1(+) cells with FKN present on activated endothelial cells may contribute to renal injury in HUS...
  64. ncbi From the mouths of babes: a response to "Should children decide whether they are enrolled in nonbeneficial research?" by David Wendler and Seema Shah
    Howard Trachtman
    Schneider Children s Hospital
    Am J Bioeth 3:W35. 2003
  65. ncbi Treatment of hyperuricemia in essential hypertension
    Howard Trachtman
    Hypertension 49:e45; author reply e46. 2007

Research Grants14

  1. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 2000
    ..The outcome of this trial may justify the use of SYNSORB PK as a safe therapy to ameliorate D+HUS. ..
  2. MULTICENTER TRIAL OF SYNSORB PK IN E COLI
    Howard Trachtman; Fiscal Year: 1999
    ..The outcome of this trial may justify the use of SYNSORB PK as a safe therapy to ameliorate D+HUS. ..
  3. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 2000
    ..The outcome of this trial may justify the use of SYNSORB PK as a safe therapy to ameliorate D+HUS. ..
  4. Novel Therapies for Resistant FSGS
    Howard Trachtman; Fiscal Year: 2006
    ..The infrastructure that is established for the performance of this R21/R33 project should prove useful for the efficient assessment of additional novel therapies that will be developed in the future for patients with primary FSGS. ..
  5. Human monoclonal antibody therapy for HUS
    Howard Trachtman; Fiscal Year: 2004
    ..abstract_text> ..
  6. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 1999
    ..The outcome of this trial may justify the use of SYNSORB PK as a safe therapy to ameliorate D+HUS. ..
  7. International Network and Registry for TMA
    Howard Trachtman; Fiscal Year: 2007
    ..These include essential hypertension, diabetes, hyperlipidemia, myocardial infarction, and chronic kidney disease. ..
  8. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 2003
    ..The outcome of this trial may justify the use of SYNSORB PK as a safe therapy to ameliorate D+HUS. ..
  9. MULTICENTER TRIAL OF SYNSORB PK IN E COLI RELATED HUS
    Howard Trachtman; Fiscal Year: 2002
    ..The outcome of this trial may justify the use of SYNSORB PK as a safe therapy to ameliorate D+HUS. ..